[New York] Precertification/prior authorization list change notification
Effective date
May 1, 2026
Identified
May 20, 2026
Summary
Effective May 1, 2026, Anthem Blue Cross and Blue Shield is adding four new services to its precertification/prior authorization requirements for New York commercial plans: PFAS testing (0589U), electrical stimulation devices for pain (E0765), allogeneic bone marrow-derived mesenchymal stromal cell therapy (J3402), and encapsulated cell therapy for degenerative ocular disease (J3403). Billing teams must implement prior auth requirements for these codes before the effective date to avoid claim denials.
Get alerts when payers change rules like this one
We check Anthem BCBS and other payers every day and email you when a change matches your specialty and state.
01Before May 1, 2026: Billing team must update the billing system and prior authorization workflows to require precertification for codes 0589U, E0765, J3402, and J3403 for all Anthem Blue Cross and Blue Shield commercial members in New York.
02Update encounter forms and provider reminders to flag these services for prior auth submission.
03Confirm Availity access is available for online prior auth submission or establish phone-based submission process via Provider Services.
04Train billing staff on the new requirements.
If missed: Failure to obtain prior authorization before service delivery will result in claim denials and potential non-payment.
Codes mentioned
E0765J3402J3403
Original notice
[New York] Precertification/prior authorization list change notification
providernews.anthem.com · Always check the source before changing claims.
Summaries are AI-assisted. Always confirm against the original payer notice.
What is PolicyChanges
One workspace for payer rules, prior auth, coding and compliance
Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.